Loading clinical trials...
Loading clinical trials...
A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily
The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.
Age
40 - No limit years
Sex
ALL
Healthy Volunteers
No
Research Site
Concord, New South Wales, Australia
Research Site
Sydney, New South Wales, Australia
Research Site
Auchenflower, Queensland, Australia
Research Site
Carina Heights, Queensland, Australia
Research Site
North Mackay, Queensland, Australia
Research Site
Adelaide, South Australia, Australia
Research Site
Daw Park, South Australia, Australia
Research Site
Clayton, Victoria, Australia
Research Site
Malvern, Victoria, Australia
Research Site
Nedlands, Western Australia, Australia
Start Date
May 1, 2007
Primary Completion Date
June 1, 2008
Completion Date
June 1, 2008
Last Updated
November 9, 2012
660
ACTUAL participants
Symbicort (budesonide/formoterol turbuhaler 320/9ug)
DRUG
Spiriva (tiotropium bromide 18ug)
DRUG
Lead Sponsor
AstraZeneca
NCT06612476
NCT02442206
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions